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Abstract
Background: Antibiotic resistance represents a significant public health problem. When resistance genes are
mobile, being carried on plasmids or phages, their spread can be greatly accelerated. Plasmids in particular have
been implicated in the spread of antibiotic resistance genes. However, the selective pressures which favour
plasmid-carried resistance genes have not been fully established. Here we address this issue with mathematical
models of plasmid dynamics in response to different antibiotic treatment regimes.
Results: We show that transmission of plasmids is a key factor influencing plasmid-borne antibiotic resistance, but
the dosage and interval between treatments is also important. Our results also hold when plasmids carrying the
resistance gene are in competition with other plasmids that do not carry the resistance gene. By altering the
interval between antibiotic treatments, and the dosage of antibiotic, we show that different treatment regimes can
select for either plasmid-carried, or chromosome-carried, resistance.
Conclusions: Our research addresses the effect of environmental variation on the evolution of plasmid-carried
antibiotic resistance.
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Background
The emergence of antibiotic resistance in pathogenic
bacteria, both in hospital and community-acquired
infections, represents a significant public health problem
[1-5]. Bacterial cells are capable of transferring genes
horizontally. This DNA transfer can take place in three
ways, through plasmids, phages, or uptake of naked
DNA [6]. Plasmids are extra-chromosomal pieces of
DNA, which are capable of replicating independently of
the genome, and are particularly important in the spread
of antibiotic resistance genes. Plasmids have been
directly implicated in the acquisition of resistance to
many antibiotics [7-14]. This is particularly problematic
since plasmids can cross many species and genus bar-
riers, and the rate of plasmid transfer has even been
shown to increase in more heterogeneous communities
[15]. Plasmids thus allow resistance to spread and per-
sist in niches that are not necessarily subject to antibio-
tics [16].
In Escherichia and Shigella strains, a larger proportion
of the genome of plasmids codes for antibiotic resistance
than that of the chromosome (Figure 1 - see figure
legend for details). However, like all mobile genetic ele-
ments, plasmids face the fundamental trade-off between
the cost of their mobility and the advantage imparted by
their accelerated spread [e.g. [17]]. Plasmids can be seen
as genomic parasites, as they can persist despite the costs
they impose on their bacterial hosts [18-20]. Previous
models have examined the conditions under which plas-
mids can be maintained in the population [18,19,21,22].
It is generally accepted that parasites can persist if their
R0, their per-capita rate of increase in a susceptible popu-
lation of hosts, is greater than 1 [23-25]. In the case of
parasitic plasmids, which do not carry beneficial traits,
a n di n f l i c tan e tc o s to nt h e i rh o s t ,t h i sm e a n st h a tt h e
rate of horizontal transfer must exceed the cost that they
impose on their host [19]. Despite being fundamentally
parasitic by nature, plasmids often carry traits which are
beneficial to a host, or a host’s neighbours [18,20,26-31].
These dynamics will likely be modulated by environmen-
tal conditions, such as antibiotic treatment. Both the
dosage of antibiotics and the interval between treatments
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tance [e.g. [18,21]]. Here we examine the role that these
parameters will have on the evolution of plasmid-borne
resistance. We address this question with a simple model
of antibiotic resistance in a population exposed to differ-
ent treatment regimes.
Methods and Results
Basic model
We start off with a population of wild-type cells ("free”
cells) that do not carry plasmids or antibiotic resistance
genes. Assuming logistic growth, with a growth rate of
r, environmental antibiotic concentration A,t h e
dynamics of the wild type nF cells are:
dnF
dt
= nF (r − mA) − an2
F (1)
The density-dependent death rate is given by a.T h i s
per capita death rate a depends on the density of cells
in the population. In a population of wild-type cells this
is simply nF, since there are no other cell types. We
assume an antibiotic-induced fitness cost Am. Antibio-
tics can have two actions on a cell: they can either kill
the bacteria (bactericidal antibiotics such as penicillin)
or they can prevent reproduction (bacteriostatic antibio-
tics, such as tetracycline). Our model is general and
does not differentiate between the two and could thus
apply to either. From equation (1), at equilibrium, dnF/
dt = 0, there are two equilibrium points, nF*=0a n dnF
*=( r-mA)/a. This implies that the antibiotic will drive
the host population extinct if mA >r. Thus, the higher
the concentration of antibiotic, the more likely it is that
wild-type will be eradicated.
To keep our model simple, we simply focus on cells
which are either resistant to the antibiotic, or not, and
where the gene is localized in the genome (on a plasmid
or a chromosome). We therefore assume that genes for
resistance against an antibiotic can be carried either by
t h ec h r o m o s o m eo rb yap l a s m i d .A ss u c h ,o u rm o d e l
does not make any other assumptions about the genetics
of the systems, such as compensatory mutations or the
number of mutations needed to confer resistance to the
antibiotic. We assume that plasmids can transfer hori-
zontally by conjugation at a rate b.T h ed y n a m i c so f
wild-type cells now becomes:
dnF
dt
=nF (r − mA) − anFN
− nF (βnP + βnCP) + snP
(2)
Details of parameters used in all models are given in
Table 1. The total population density is given by N = nF
+nP+nC+nCP,w h e r enP is the density of wild-type cells
which are infected by a plasmid carrying a gene for anti-
biotic resistance and nCP is the density of cells which
both carry a gene for antibiotic resistance on the chro-
mosome and are infected by a plasmid carrying a gene
for antibiotic resistance. We assume that cells which
c a r r yag e n ef o ra n t i b i o t i cr e s i s t a n c ea r ef u l l yi m m u n e
to the effects of the antibiotic (although we later relax
this assumption).
Figure 1 Percentage of the genome among 37 Escherichia and
Shigella strains which code for genes related to antibiotic
resistance. This shows that antibiotic resistance genes are over-
represented on plasmids. Bars show the mean percentage (±s.e.) in
all replicons (either on the chromosome, n = 37, or on plasmids, n
= 53, including 38 plasmid genomes which contained no antibiotic
resistance genes). The genomes are from 37 Escherichia and Shigella
strains, including all chromosomal and plasmid genes in each
genome (data obtained from the NCBI at http://www.ncbi.nlm.nih.
gov/genomes/). There were a total of 174,862 genes, with 170,709
on all 37 chromosomes and 4,153 on all 53 plasmids. For
comparison with known genes involved in antibiotic resistance, the
“Antibiotic Resistance Database” [http://ardb.cbcb.umd.edu/- [62]]
was used to identify genes involved in antibiotic resistance
(homologues were identified using an E-value of 10
-10 and
percentage of sequence identity between 60-95%). From this, there
were a total of 817 genes involved in antibiotic resistance, with 765
carried by the bacterial chromosomes (and 0.48% of all
chromosomal genes) and 52 carried by plasmids (1.25% of all
plasmid genes). A c
2 test revealed that antibiotic resistance genes
were significantly over-represented on plasmids, compared to on
the bacterial chromosome (Pearson’s c
2 with Yates’ continuity
correction: c
2 = 54.6, p <1 0
-12, df = 1).
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carrying individual [32-37], which we denote cC in the
case of chromosome-carried resistance and cP in the
case of plasmid-carried resistance. The dynamics of
chromosome-carried resistance genes are:
dnC
dt
=nC (r − cC) − anCN
− nC (βnP + βnCP) + snCP
(3)
Building on previous models of the dynamics of plas-
mid carriage [18,19,38,39], and assuming that plasmids
are fundamentally genomic parasites [18-22], we assume
that there is a cost x to a cell from plasmid carriage.
The dynamics of plasmid-infected cells are therefore:
dnP
dt
=nP (r − cP − x) − anPN
+ βnPnF + βnFnCP − snP
(4)
Cells with resistance on the chromosome can also be
infected by plasmids. In this case there will be multiple
copies of the gene and the cell will pay the cost of carrying
both genes (i.e. cC + cP). The dynamics for such cells are:
dnCP
dt
=nCP (r − cC − cP − x) − anCPN
+ βnCnCP + βnPnC − snCP
(5)
Analytical results
From equations (1)-(5), we can look at the conditions
under which resistance (either carried by plasmids or
coded on the chromosome) will invade. The condition
under which a cell with resistance on the chromosome
will invade, if wild-type cells are at equilibrium nF*=( r-
mA)/a (and if there are no other cells in the popula-
tion), is if
Am > cC
This occurs if the net benefit (Am) from being resis-
tant to the antibiotic is greater than the costs cC of
resistance. When the wild-type cells are at equilibrium
(and there are no other cells in the population), a plas-
mid carrying the resistance gene will invade if
β(r − mA)/a + mA > x + s + cp
This shows that lower costs (in terms of x, s and cP),
higher rates of transfer of the plasmid given by b(r-mA)/
a, or greater impact of the antibiotic on wild-type cells
(given by mA) will all favour the invasion of plasmid
resistance.
Plasmids will be selected to carry antibiotic resistance
genes if the fitness of cells with resistance on a plasmid
is greater than the fitness of cells with resistance on a
chromosome. Plasmid-bearing cells will grow faster than
cells with resistance on the chromosome when both are
rare (i.e. nP®0, nC®0, nCP®0) if the following condi-
tion is fulfilled:
∂

dnP/dt

∂nP
 
 

nP→0,nC→0,nCP→0
>
∂

dnC/dt

∂nC
 
 

nP→0,nC→0,nCP→0
(7)
From inequality 7, we find that the plasmid will be
favoured if
nFβ > x + s + cp − cc (8)
This shows that plasmids cannot invade the popula-
tion if there are no wild-type cells (i.e. nF = 0). As the
antibiotic will kill wild-type cells, cells with resistance
on the chromosome will be favoured over cells with
resistance on a plasmid if the antibiotic has substan-
tially reduced the density nF of wild-type cells. Plas-
mid-carried resistance will also be favoured over
chromosome-carried resistance if the costs of expres-
s i n gar e s i s t a n c eg e n eo nt h ec h r o m o s o m ecC,i s
greater than the cost of expressing a resistance gene
on a plasmid cP.
If the antibiotic fails to completely eradicate the popu-
lation of wild-type cells, a wild-type population with no
plasmids will have an equilibrium density of nF*=( r-
Am)/a, assuming that the concentration of antibiotics is
not enough to drive them extinct (which requires that r
Table 1 Parameters used in the model
Parameter Description
nF Density of wild-type/plasmid-free cells (’F’ in figures)
nC Density of cells with resistance on the chromosome (’C’ in
figures)
nP Density of cells infected with a resistance-carrying plasmid
(’Plasmids’ in figures)
nB Density of cells infected with a non-coding plasmid (’B’ in
figures)
nCP Density of cells with resistance both on the chromosome
and on a plasmid (’CP’ in figures)
nCB Density of cells infected with a non-coding plasmid, and
with resistance on the chromosome (’CB’ in figures)
N Total density of cells
N = nF+nC+nP+nB+nCP+nCB
A Concentration of antibiotic
l Rate of decay of antibiotic
θ Treatment dosage of antibiotic
τ Interval between antibiotic treatments
r Intrinsic per-capita growth rate of cells
a Extrinsic density-dependent death rate of cells
m Death rate of non-resistant cells, due to antibiotic
cC Cost of antibiotic resistance when gene carried on
chromosome
cP Cost of antibiotic resistance when gene carried on plasmid
x Cost of plasmid carriage
b Rate of horizontal transfer of plasmids
s Rate of segregation
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favoured over chromosomal resistance when
β(r − Am)/a > x + s + cp − cc
This implies that higher per-capita growth rate, or low
doses of antibiotic, will favour plasmid-borne resistance.
Consequently, plasmids will be favoured when the wild-
type density is not much constrained by antibiotic-
induced mortality. Plasmids will have a faster growth
rate than wild-type cells (cells without any resistance
gene or plasmid) if
∂

dnP/dt

∂nP
 
 

nP→0,nC→0,nCP→0
>
∂

dnF/dt

∂nF
 
 

nP→0,nC→0,nCP→0
which will occur when
F(a + β)+ Am > x + s + cp
When the wild-type cells are at equilibrium nF*=( r-
Am)/a then this criteria becomes:
(ra + β (r − mA))/a > x + s + cp
T h i ss h o w st h a th i g h e rt r a n s f e rr a t e sb of the plasmid,
as well as a greater effect of the antibiotic, or lower over-
all costs from carrying the plasmid (x +s + cp) will all
result plasmid-carried resistance have a greater over all
rate of spread than wild-type cells. Interestingly, greater
growth rates r will also favour plasmid-carried resistance
to have a larger growth rate than wild-type cells.
Numerical analysis model
We now explore how different treatments select for
antibiotic resistance to be carried either on a plasmid,
or a chromosome, using numerical simulations of our
system. We built a numerical simulation to investigate
how dosage strength and interval affect whether resis-
tance will be found on the host chromosome or a plas-
mid. We start with a population of wild-type cells at the
carrying capacity (i.e. nF = 1). Following [40], we assume
exponential degradation at a rate l for the antibiotic:
dA
dt
= −lA (6)
We use the Euler method of integration with a time
step of 0.001. Once the cells are at the equilibrium den-
sity, we then assume that the antibiotic is introduced, at
ad o s a g eo fθ.W et h e na s s u m et h a ta na m o u n tθ of the
antibiotic is re-introduced in regular treatment intervals
of τ time-steps. At the beginning of the simulation, we
assume that only 0.1% of cells contain the resistance
gene, and these are carried either on a plasmid or on the
host chromosome (i.e. nC = 0.001 and nP = 0.001 at the
start of the simulation). We then run the simulation for
5,000 time-steps, or until the cells have reached a stable
dynamical equilibrium. Examples of the dynamics of the
model are given in Figure 2, illustrating the case where
the interval is either 5 (top panel) or 50 (bottom panel).
Figure 3 shows the qualitative outcome for a large set
of treatment intervals and dosages. The boundaries were
interpolated for increased clarity. Under the conditions
shown in Figure 3, chromosomal resistance does not
evolve, and that lower intervals between treatments, or
high dosages of antibiotics, increasingly favour a popula-
tion only consisting of plasmid resistance, as the wild-
type cells are killed by the antibiotic. However, as
shown with our analytical model, the strain that wins
depends strongly on the transmission rate (Additional
File 1). In the case that the transmission rate beta is
low, chromosomal resistance will be favoured if the
interval is short and the treatment dosage is high, while
as the transmission rate increases, plasmids increasingly
dominate across the population. These confirm the
results of our analytical model and suggest that trans-
mission is the most important factor promoting plas-
mid-carried resistance.
Model with non-coding plasmids
Up to now, we used the simplifying assumption that
plasmids would always carry resistance genes. It has
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Figure 2 Dynamics of the basic model (consisting of wild-type
cells, cells with resistance on the chromosome and plasmid-
carried resistance) in response to different treatment regimes.
“F” denotes wild-type cells, “P” denotes cells infected with a plasmid
carrying resistance, “C” denotes cells with resistance on the
chromosome and “CP” stands for cells with resistance on the
chromosome that also carry a resistance plasmid. Parameters used
are r =1 ,a =1 ,b = 0.006, s = 0.001, cc = 0.002, cp = 0.002, x =
0.002, m = 0.1 and l = 0.005. The dosage is 50 in both panels, while
the treatment interval is τ = 5 time units in the top panel and τ =
50 time units in the bottom panel. Time in our model is scaled, and
is thus measured in arbitrary units (AU).
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the focal gene can have a substantial impact on the
invasion of horizontally-transferred genes [39]. While a
significant proportion of the genome of plasmids is
involved in antibiotic resistance, many plasmids contain
no genes involved in antibiotics at all (Figure 1 - see fig-
ure legend for details). Thus, we now additionally con-
sider plasmids which are infectious, but do not code for
resistance, which we refer to as “non-resistant plasmids”.
These cells pay a cost of plasmid carriage, but do not
carry resistance to the antibiotic, and are therefore sus-
ceptible to the antibiotic. The dynamics of wild-type,
cells with resistance on the chromosome and cells with
resistance on a plasmid now become:
dnF
dt
=nF (r − Am) − anFN − βnF (nP + nCP + nB + nCB)
+ s(nP + nB)
(9)
dnC
dt
=nC (r − cC) − anCN − βnC (nP + nCP + nB + nCB)
+ s(nCP + nCB)
(10)
dnP
dt
=nP (r − cP − x) − anPN + βnPnF
+ βnCPnF − snP
(11)
We assume that non-resistant plasmids are incompati-
ble with resistance plasmids, and hence a cell can be
infected by only one type of plasmid. The density of
cells infected with non-resistant plasmids nB is given by:
dnB
dt
=nB (r − x − Am) − anB + βnFnB
+ βnFnCB − snB
(12)
The density of cells which carry resistance on both the
chromosome, and on a plasmid, is given by nCP.T h e
dynamics of these cells are:
dnCP
dt
=nCP (r − cC − cP − x) − anCPN
+ βnCPnC + βnCnP − snCP
(13)
Finally, we also assume that cells which have resis-
tance on the chromosome can be infected with a non-
resistant plasmid, and in this case the cell pays the cost
x of bearing a plasmid and the cost cc of antibiotic resis-
tance. The density of such cells is given by nCB and
their dynamics is given by:
dnCB
dt
=nCB (r − cC − x) − anCBN
+ βnCBnC + βnCnB − snCB
(14)
In the basic model, plasmids were favoured due to
their ability to transfer infectiously. In the absence of
antibiotics, non-resistant plasmids will outcompete resis-
tance plasmids, because resistance plasmids additionally
pay the cost of antibiotic resistance gene expression cP.
As in the basic model, we assume that the antibiotic
degrades at an exponential rate described by equation 6.
We analyse the system described by equations 9-14
using the numerical method described in the previous
s e c t i o n ,b u th e r ew es t a r ta tt h ep o i n tw h e r eb o t hnF
and nB have reached equilibria (i.e. the population
already consists of wild-type cells and non-resistant
plasmids coexisting), before introducing a small number
of cells with resistance on the plasmid, or on the chro-
mosome, respectively (i.e. nP =0 . 0 1 ,nC =0 . 0 1 ,nCP =0 ,
nCB = 0 at the start of the simulation).
Figure 4 shows examples of the dynamics that result for
different treatment regimes. Figure 5 shows the condi-
tions under which resistant plasmids persist under a wide
range of different treatment regimes. This shows that
plasmid-carried resistance is favoured under more
intense, but less frequent, treatment regimes. Figure 5
shows that plasmids that carry resistance are outcom-
p e t e db yc e l l sw i t hr e s i s t a n c eo nt h ec h r o m o s o m ea t
lower dosages and shorter treatment intervals (Figure 5).
In contrast, non-resistant plasmids are favoured only
when there is a low dosage of antibiotic applied with long
intervals between treatments. Under weak treatments,
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Figure 3 The effect of antibiotic dosage intensity and the
interval between treatments on the cell types persisting at
equilibrium for the basic model (consisting of wild-type cells,
cells with resistance on the chromosome and plasmid-carried
resistance). Here, chromosomal resistance can be outcompeted by
plasmid-carried resistance. “F” denotes wild-type cells and “P”
denotes cells infected with a plasmid carrying resistance. Cell types
that are present in the population at a density greater than
exceeding 0.001 are shown. The plots were calculated by running
the simulation for a number of parameter values for 5,000 time-
steps. Lines were then smoothed by interpolation. Parameters used
are r =1 ,a =1 ,b = 0.1, cc = 0.02, cp = 0.02, x = 0.05, m = 0.1, s =
0.001 and l = 0.5.
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Page 5 of 10the non-resistant plasmids outcompete plasmids carrying
the resistance gene due to the costs cp of expressing the
resistance gene. In general, the results of our extended
model support our basic model, and confirm our predic-
tions that plasmid-coded resistance will outcompete
chromosomally-coded resistance under long-interval
treatment regimes.
It is likely that cells that have resistance genes on a
plasmid will be less susceptible to the antibiotic than
cells which have resistance genes on a plasmid. To
explore this, we looked at the case where all cell types
could have differing levels of susceptibility. In this case,
cells with resistance on the chromosome suffered a mor-
tality of m = 0.002 per cell per unit of antibiotic, while
cells with resistance on a plasmids suffered a mortality
of m = 0.001 per cell per unit of antibiotic. If a cell car-
ried the resistance gene both on the chromosome, or on
a plasmid, we assumed the effective of having both
genes would be additive, and the antibiotic-induced
mortality of 0.000002 (i.e. the product of the two mor-
talities). As in the previous models, any cell which did
not have either resistance gene suffered a per unit anti-
biotic mortality of m = 0.1. The results are plotted in
Figure 6 (this is in comparison to Figure 5 as the com-
parison case where resistance is 100% effective). In this
case, more intensive treatment regimes (i.e. high
dosages, with short intervals between doses) favour a
cells with both resistance on a plasmid and on the chro-
mosome (Figure 6). This is in contrast to the case where
resistance is 100% effective, where only cells carrying
resistance on the plasmid persist at intensive treatment
regimes.
We further explored our results for different para-
meter value combinations, such as the transmission rate
(Additional Files 1 and 2), the segregation rate (Addi-
tional File 3), the respective cost of having resistance on
a plasmid or a chromosome (Additional File 4) and the
mortality cost m and the degradation rate l of the anti-
biotic (Additional File 5). All graphs can be found in the
supplementary material. Our results generally held when
changing these parameter values.
Discussion
Plasmids are favoured when their rate of horizontal
transfer outweighs the costs involved in plasmid carriage
to a cell [19]. However, in the presence of less costly
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Figure 4 Dynamics of the full model (consisting of wild-type
cells, cells with resistance on the chromosome, plasmids
carrying resistance and plasmids with no resistance) in
response to different treatment regimes. “F” denotes wild-type
cells, “P” denotes cells infected with a plasmid carrying resistance,
“C” denotes cells with resistance on the chromosome, “B” denotes
cells infected plasmids which do not carry the resistance gene, and
“CP” and “CB” stand for the chromosomally resistant cell types also
carrying the respective plasmid. Parameters used are r =1 ,a =1 ,b
= 0.1, s = 0.001, cc = 0.02, cp = 0.02, x = 0.05, m = 0.1 and l = 0.5.
The dosage is 50 in the top two panels and 5 in the bottom panel,
while the treatment interval is τ = 1 in the top panel and τ =8 0i n
the bottom two panels.
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Figure 5 The effect of antibiotic dosage intensity and the
interval between treatments on the cell types persisting at
equilibrium for the full model (consisting of wild-type cells,
cells with resistance on the chromosome, plasmids carrying
resistance and plasmids with no resistance). “F” denotes wild-
type cells, “P” denotes cells infected with a plasmid carrying
resistance and “C” denotes cells with resistance on the chromosome
and “B” denotes cells carrying plasmids that do not code for
resistance genes. Here, plasmid-carried resistance is favoured when
dosage and interval between treatments are high. Cell types that
are present in the population at a density greater than exceeding
0.001 are shown. The plots were calculated by running the
simulation for a number of parameter values for 5,000 time-steps.
Lines were then smoothed by interpolation. Parameters used are r =
1, a =1 ,b = 0.1, cc = 0.02, cp = 0.02, x = 0.05, m = 0.1, s = 0.001
and l = 0.5.
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Page 6 of 10plasmids, the benefit of transfer disappears [39]. In our
basic model in the absence of non-resistant plasmids,
plasmids can persist as long as the rate of transfer is
sufficient (Figure 3, Additional File 1). Our full model,
incorporating non-resistant plasmids, shows that resis-
tant plasmids outcompete non-resistant plasmids under
higher dosages, and outcompete cells which resistance
on the chromosome under longer intervals between
treatments (Figures 5 and 6). This is due to horizontal
gene transfer: wild-type cells are common when treat-
ment is weak and their presence allows plasmids to
invade. Resistance genes encoded by the host genome
are favoured by treatment regimes that result in a con-
tinual presence of antibioitic. We can understand this
intuitively by considering that the infectious mainte-
nance of plasmids in a population consisting only of
plasmid-carrying and wild-type cells requires the
availability of plasmid-free cells. This is because carrying
a plasmid and expressing resistance has a cost which
has to be offset by the benefit of infecting susceptible
cells. When susceptible cells are killed by antibiotics,
plasmids suffer indirectly as they have fewer cells to
infect. It is worth noting that our model assumes rela-
tively efficient horizontal transfer, and thus our results
may change if plasmids do not transmit themselves well.
Our model would therefore predict that plasmids with
lower transmission rates would not carry genes for anti-
biotic resistance. However the generality of our model
of horizontal transfer of plasmids means that our find-
ings will apply to other vehicles of gene transfer, such as
phages.
We assumed that chromosomal- and plasmid-borne
resistant types were phenotypically identical. This may
not be the case [41] as changes in gene dosage can
influence the resistance level [42-47]. We predict that
higher gene dosage from multi-copy plasmids would
enlarge the treatment space beneficial to plasmids, due
to the additional resistance compared to chromosomally
carried resistance genes. In the absence of antibiotics,
hosts carrying multiple copies of resistance genes would
be at a disadvantage due to the extra cost of producing
more antibiotic resistance proteins. An important result
of our study is to illustrate how the ecology of the bac-
teria, in this case the density of wild-type cells (mediated
by the concentration of antibiotic), affects the conditions
under which plasmid-borne resistance is favoured.
Our model makes qualitative predictions regarding the
conditions under which antibiotic resistance genes will
be selected to be carried on plasmids, as opposed to on
the chromosome. Specifically, we were interested in ask-
ing whether the intensity and interval between treat-
ments will select for resistance to be on a plasmid, or
on a chromosome. However, we find that our results
generally hold under a wide range of different parameter
ranges (see supplementary material for details). There is
aw i d er a n g eo fl i t e r a t u r ea v a i l a b l ew i t hw h i c hs u c h
models could be parameterised, and it would be possible
to design models to test when selection will result in
resistance to be carried on plasmids. For example, it is
possible to add more realism to model the pharmacody-
namics of drugs and how they kill bacteria [e.g. [40,48]],
and there are some studies from which the costs of anti-
biotic resistance can be estimated [for example, see
references in [49]]. Rates of horizontal gene transfer
range widely and in the case of conjugation can range
between 10
-3 and 10
-1 per donor in biofilms and more
than 10
-5 i nw a t e ro rs o i l[ 5 0 - 5 2 ] .A sp l a s m i d sh a v e
been described as the Achilles’ heal of drug resistant
bacteria [53,54], understanding the conditions under
which antibiotic resistant genes are carried by plasmids
could help to develop strategies to minimise the spread
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Figure 6 The effect of antibiotic dosage intensity and the
interval between treatments on the cell types persisting at
equilibrium for the full model (consisting of wild-type cells,
cells with resistance on the chromosome, plasmids carrying
resistance and plasmids with no resistance) without
segregation (i.e. s =0 ) . Here, plasmid-carried resistance is favoured
over non-resistant plasmids at higher dosages, but shorter
treatment intervals, but are favoured over chromosomal resistance
at lower dosages but longer treatment intervals. This figure shows
the case where all cells are susceptible to the antibiotic but where
“C” cells suffer a mortality of m = 0.002, “P” cells suffer a mortality of
m = 0.001 and “CP” cells have a combined mortality of 0.000002
(the product of the two mortalities). Wilt-type cells suffer a mortality
m = 0.1. “F” denotes wild-type cells, “P” denotes cells infected with
a plasmid carrying resistance and “C” denotes cells with resistance
on the chromosome and “B” denotes cells carrying plasmids that do
not code for resistance genes. Cell types that are present in the
population at a density greater than exceeding 0.001 are shown.
The plots were calculated by running the simulation for a number
of parameter values for 5,000 time-steps. Lines were then smoothed
by interpolation. Parameters used are r =1 ,a =1 ,b = 0.1, cc = 0.02,
cp = 0.02, x = 0.05 and l = 0.5.
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explicit models in combination with laboratory studies,
in contrast to the simple qualitative models described
here, will be essential to developing treatments than
minimise the rates of transfer.
The use of multiple antibiotics and antibiotic cycling
has been proposed as a way to prevent the evolution of
antibiotic resistance [e.g. [55]]. A previous study showed
that plasmids could play a role in the acquisition of
multiple drug resistance by repeated gene transfer [56].
Thus, plasmids may reduce the effect of antimicrobial
cycling, as multiple resistance could be acquired more
quickly. In the case of multidrug therapy, we would pre-
dict that the results of our model would hold, and
longer intervals between treatment regimes would
favour plasmid-carried resistance, which would in turn
favour the evolution of multiple resistance.
Given the biological variability in the mechanisms of
resistance, horizontal transfer and persistence, some of
our assumptions may not hold in specific settings. Our
work rests on costly antibiotic resistance and should
thus apply particularly to mechanisms that need to be
strongly expressed or that require a lot of cellular
energy. When resistance proteins catalyse reactions that
modify the antibiotic, such as in the case of b-lacta-
mases, chloramphenicol acetyltransferase or aminoglyco-
side acetyltransferases, a higher expression level is
expected to translate to a higher resistance level and the
cell will have to pay high protein synthesis costs in
order to be resistant. The same is true for efflux pumps,
such as ABC -transporters or MF-type pumps [57]. The
cost of resistance plasmids, including the cost of mainte-
nance and expression, could be significantly ameliorated
in experimental evolution experiments [58-60]. Based on
the above arguments and the fact that even small costs
are significant over evolutionary timescales, we expect
t h e r et ob eal a r g en u m b e ro fe n v i r o n m e n t si nw h i c h
our findings would hold despite this effect, but it illus-
trates that with respect to the clinical view on this fun-
damental problem, more detailed case-by-case analyses
will be required.
Conclusions
To the best of our knowledge, our study represents the
first model to explicitly examine the effect of treatment
regimes plasmid-borne antibiotic resistance. We show
that high transmission favours plasmid-carried resis-
tance, in the absence of competing non-resistant plas-
mids. When other plasmids are present, low frequency
treatments favour plasmid-carried resistance over chro-
mosomal resistance, but a high intensity of antibiotic is
needed for resistance plasmids to outcompete non-resis-
tance plasmids. Targeting plasmid spread has been pro-
p o s e dt om a n a g ea n t i b i o t i cr e s i s t a n c e[ 5 4 ]a n do u r
results suggest that paying attention to the treatment
regime is an essential requirement of any such strategy.
The solution, as recommend by Paul Ehrlich almost a
century ago, is to “h i th a r da n dh i tq u i c k l y ” [61]. Gain-
ing a quantitative understanding of the dynamics of
plasmids will allow us to understand harmful patterns of
antibiotic use more effectively.
Additional material
Additional file 1: The effect of antibiotic dosage intensity and the
interval between treatments on the cell types persisting at
equilibrium for the basic model in the absence of segregation (i.e. s
=0 ) . “F” denotes wild-type cells, “P” denotes cells infected with a
plasmid carrying resistance and “C” denotes cells with resistance on the
chromosome. Plasmid transmission is b = 0.01 (in figure A) and b = 0.1
(in figure B). Cell types that are present in the population at a density
greater than exceeding 0.001 are shown. The plots were calculated by
running the simulation for a number of parameter values for 5,000 time-
steps. Lines were then smoothed by interpolation. Parameters used are r
=1 ,a =1 ,cc = 0.02, cp = 0.02, x = 0.05, m = 0.1, s = 0 and l = 0.5.
Additional file 2: The effect of antibiotic dosage intensity and the
interval between treatments on the cell types persisting at
equilibrium for the extended model, in the absence of segregation
(i.e. s =0 ) . “F” denotes wild-type cells, “P” denotes cells infected with a
plasmid carrying resistance and “C” denotes cells with resistance on the
chromosome and “B” denotes cells carrying plasmids that do not code
for resistance genes. Plasmid transmission is b = 0.01 (in figure A) and b
= 0.1 (in figure B). Cell types that are present in the population at a
density greater than exceeding 0.001 are shown. The plots were
calculated by running the simulation for a number of parameter values
for 5,000 time-steps. Lines were then smoothed by interpolation.
Parameters used are r =1 ,a =1 ,c c = 0.02, cp = 0.02, x = 0.05, m = 0.1, s
= 0 and l = 0.5.
Additional file 3: The effect of antibiotic dosage intensity and the
interval between treatments on the cell types persisting at
equilibrium for the extended model. “F” denotes wild-type cells, “P”
denotes cells infected with a plasmid carrying resistance and “C” denotes
cells with resistance on the chromosome and “B” denotes cells carrying
plasmids that do not code for resistance genes. Plasmid segregation s =
0.01 (in figure A) and s = 0.0001 (in figure B). Cell types that are present
in the population at a density greater than exceeding 0.001 are shown.
The plots were calculated by running the simulation for a number of
parameter values for 5,000 time-steps. Lines were then smoothed by
interpolation. Parameters used are r =1 ,b = 0.1, a =1 ,c c = 0.02, cp =
0.02, x = 0.05, m = 0.1 and l = 0.5.
Additional file 4: The effect of antibiotic dosage intensity and the
interval between treatments on the cell types persisting at
equilibrium for the extended model. “F” denotes wild-type cells, “P”
denotes cells infected with a plasmid carrying resistance and “C” denotes
cells with resistance on the chromosome and “B” denotes cells carrying
plasmids that do not code for resistance genes. The cost of antibiotic
resistance is either cc = 0.04, cp= 0.02 (in figure A) or cc = 0.02, cp = 0.04
(in figure B), in the absence of segregation (i.e. s = 0). Cell types that are
present in the population at a density greater than exceeding 0.001 are
shown. The plots were calculated by running the simulation for a
number of parameter values for 5,000 time-steps. Lines were then
smoothed by interpolation. Parameters used are r =1 ,b = 0.1, a =1 ,x =
0.05, m = 0.1, s = 0 and l = 0.5.
Additional file 5: The effect of antibiotic dosage intensity and the
interval between treatments on the cell types persisting at
equilibrium for the extended model, in the absence of segregation
(i.e. s =0 ) . In Figures A, C and E the degradation rate of the antibiotic is
l = 0.1, while in Figures A, C and E, the degradation rate of the antibiotic
is l = 5. In figures A and B the antibiotic induced mortality is m = 0.0001,
in figures C and D the antibiotic induced mortality is m = 0.01 and in
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Page 8 of 10figures E and F the antibiotic induced mortality is m =1 .“F” denotes
wild-type cells, “P” denotes cells infected with a plasmid carrying
resistance and “C” denotes cells with resistance on the chromosome and
“B” denotes cells carrying plasmids that do not code for resistance genes.
Cell types that are present in the population at a density greater than
exceeding 0.001 are shown. The plots were calculated by running the
simulation for a number of parameter values for 5,000 time-steps. Lines
were then smoothed by interpolation. Parameters used are r =1 ,a =1 ,
b = 0.1, cc = 0.02, cp = 0.02, x = 0.05 and s =0 .
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